Norges Bank’s Aligos Therapeutics ALGS Stock Holding History

Norges Bank’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,096	Closed	-$1.59M	–	2208
2021 Q3	$1.59M	Buy	+4,096	New	+$1.62M	﹤0.01%	2090

Other funds holding ALGS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Norges Bank's ALGS Position: Q4 2021 in Review

Norges Bank sold out of Aligos Therapeutics (ALGS) in Q4 2021, closing a stake of 4,096 shares — an estimated $1.59M sold.

Norges Bank first reported a position in ALGS in Q3 2021 and held it in 1 quarter. The position peaked at $1.59M in Q3 2021. 71 funds tracked by Wall St. Rank hold ALGS as of Q4 2021.

Norges Bank reported no remaining Aligos Therapeutics position as of Q4 2021 after selling out during the quarter.
Norges Bank sold 4,096 Aligos Therapeutics shares in Q4 2021, an estimated $1.59M.
Norges Bank first reported a position in Aligos Therapeutics in Q3 2021 and held it in 1 quarter.
Norges Bank's Aligos Therapeutics position peaked at $1.59M in Q3 2021.
71 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2021.

Based on Norges Bank's 13F filing for Q4 2021, filed 10 Feb 2022.